Pulmonx Co. (NASDAQ:LUNG) Receives $12.75 Consensus Price Target from Analysts

Pulmonx Co. (NASDAQ:LUNG) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.75.

LUNG has been the subject of a number of research analyst reports. Stifel Nicolaus cut their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Wells Fargo & Company decreased their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th.

Pulmonx Trading Up 0.8 %

NASDAQ:LUNG opened at $6.68 on Thursday. Pulmonx has a 1 year low of $5.46 and a 1 year high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The stock has a fifty day moving average price of $6.34 and a two-hundred day moving average price of $6.74. The stock has a market capitalization of $263.79 million, a price-to-earnings ratio of -4.54 and a beta of 0.64.

Insider Activity at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the transaction, the director now owns 1,071,974 shares of the company’s stock, valued at $7,107,187.62. This trade represents a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel David Aaron Lehman sold 5,497 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the transaction, the general counsel now owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. The trade was a 2.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,199 shares of company stock valued at $208,859. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LUNG. 272 Capital LP bought a new stake in shares of Pulmonx during the 3rd quarter worth about $25,000. nVerses Capital LLC acquired a new position in shares of Pulmonx in the 3rd quarter worth approximately $26,000. R Squared Ltd bought a new stake in shares of Pulmonx in the 4th quarter worth approximately $46,000. SG Americas Securities LLC acquired a new stake in Pulmonx during the third quarter valued at approximately $102,000. Finally, Rhumbline Advisers boosted its holdings in Pulmonx by 4.9% during the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after buying an additional 2,488 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.